Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. report that they have entered into a worldwide collaboration agreement for the development and commercialization of Eisai’s clinical candidate lemborexant, a dual orexin receptor antagonist entering Phase III clinical development for the treatment of insomnia.

Under the terms of the agreement, Eisai and Purdue Pharma will share the costs of lemborexant global clinical studies. While the potential indication for the product candidate is for the treatment of insomnia, the companies may also seek to develop other indications in the future.